Results 171 to 180 of about 8,038,703 (314)
Patching Power System Software Vulnerability Using CNNVD
Qinqin Wu +6 more
openalex +2 more sources
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Automated Cloud-to-Cloud Migration of Distributed Software Systems for Privacy Compliance
Philipp Weimann
openalex +1 more source
EUNOMIA (ΕΥΝΟΜIΑ): A REQUIREMENT ENGINEERING BASED COMPLIANCE FRAMEWORK FOR SOFTWARE SYSTEMS [PDF]
PRISCILA ENGIEL
openalex +1 more source
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
Software System Design to Support Scale in Mammalian Cell Line Engineering. [PDF]
McClymont DW +4 more
europepmc +1 more source
Formal modeling and analysis of resource usage and sharing in distributed software systems [PDF]
Ivan Prokić
openalex
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source

